TargetMol
 |
||
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, specializing in chemical and biological research products and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global small molecule suppliers with over 5000 inhibitors and 80+ compound libraries in stock. TargetMol offers a wide range of high quality research chemicals including novel life-science reagents, inhibitors, activator, APIs and natural compounds for laboratory and scientific use. Website : www.targetmol.com | ||
SARS-CoV-2 - Baricitinib - Therapeutic Candidates
Like ruxolitinib, baricitinib (OLUMIANT) is an inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) which are tyrosine kinases involved in JAK signaling pathways. Baricitinib is a reversible and selective inhibitor and is indicated in the treatment of moderate to severe active rheumatoid arthritis for its anti-inflammatory effect. It is a second-line therapy, i.e., used after failure of conventional disease-modifying therapies. It can be used alone or in combination with methotrexate (MTX).
A clinical study on the efficacy and safety of baricitinib for the treatment of Covid-19 has begun. The anti-inflammatory activity of this drug may have a potential beneficial effect in the treatment of Covid-19. The use of baritinicib therapy may limit the cytokine release syndrome associated with Covid-19 and may be useful because it acts against a wide range of cytokines.
Resultados de su búsqueda : 13 Producto encontrado
Refine su búsqueda :
RUOCE / IVD
- Biochemicals 13
Referencia
Descripción
Cond.
Precio Sin IVA
‹
›